- Home
- GMM vs ADAP Comparison
GMM vs ADAP Comparison
Compare GMM & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- ADAP
- Stock Information
- Founded
- GMM 2017
- ADAP 2008
- Country
- GMM China
- ADAP United Kingdom
- Employees
- GMM N/A
- ADAP N/A
- Industry
- GMM
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- GMM
- ADAP Health Care
- Exchange
- GMM Nasdaq
- ADAP Nasdaq
- Market Cap
- GMM 70.8M
- ADAP 75.5M
- IPO Year
- GMM 2023
- ADAP 2015
- Fundamental
- Price
- GMM $2.79
- ADAP $0.28
- Analyst Decision
- GMM
- ADAP Buy
- Analyst Count
- GMM 0
- ADAP 6
- Target Price
- GMM N/A
- ADAP $1.52
- AVG Volume (30 Days)
- GMM 25.2K
- ADAP 1.6M
- Earning Date
- GMM 06-10-2025
- ADAP 05-13-2025
- Dividend Yield
- GMM N/A
- ADAP N/A
- EPS Growth
- GMM 62.17
- ADAP N/A
- EPS
- GMM 6.37
- ADAP N/A
- Revenue
- GMM $41,360,953.00
- ADAP $179,639,000.00
- Revenue This Year
- GMM N/A
- ADAP N/A
- Revenue Next Year
- GMM N/A
- ADAP $52.49
- P/E Ratio
- GMM $0.44
- ADAP N/A
- Revenue Growth
- GMM 53.82
- ADAP 878.53
- 52 Week Low
- GMM $1.69
- ADAP $0.20
- 52 Week High
- GMM $15.60
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- GMM 51.23
- ADAP 49.68
- Support Level
- GMM $2.64
- ADAP $0.26
- Resistance Level
- GMM $2.99
- ADAP $0.30
- Average True Range (ATR)
- GMM 0.31
- ADAP 0.03
- MACD
- GMM 0.02
- ADAP 0.00
- Stochastic Oscillator
- GMM 51.72
- ADAP 54.53
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.